Sangamo Biosciences, Inc. (SGMO) Posts Q3 EPS Loss of $0.18, Sales Fall Short
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.82 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Traws Pharma (TRAW) Tops Q2 EPS by 27c
- The LGL Group (LGL) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
